Moderna’s 530% Rally Gets a 25% Reality Check After Cancer Vaccine Results Leak on X

Moderna shares crashed as much as 25% Thursday after results from its cancer vaccine trial leaked online. What's surprising is that the vaccine, developed with Merck, actually showed promising results. 

The trouble started when details from the closely watched trial began circulating on X, just days before the companies were supposed to present their findings at the European Society for Medical Oncology conference in Madrid this weekend.

One account shared what appeared to be a report from Oncology Central showing that the experimental vaccine, called intismeran autogene, reduced the risk of melanoma returning or causing death by 42% when combined with Merck's cancer drug Keytruda. The link to the report didn't work, making it difficult to verify the information.

Moderna and Merck eventually released the full results Thursday, confirming that the leaked figures were accurate. The combination reduced the risk of cancer recurrence or death by 42% compared with Keytruda alone. It also lowered the risk of cancer spreading to other parts of the body or death by 38%.

Those are encouraging results for a treatment that could eventually change how certain cancers are treated. But investors had been hoping for something even better.

An earlier study of the vaccine showed a 49% reduction in cancer recurrence or death, along with a 59% reduction in the risk of cancer spreading or death. While the two studies involved different patients and observation periods, making direct comparisons difficult, the lower figures appeared to disappoint investors.

That reaction also has a lot to do with how much Moderna's stock had already climbed.

Shares were up more than 530% this year through Thursday afternoon, largely because investors were betting that the cancer vaccine could become a major new source of revenue for the company.

The treatment itself works differently from traditional vaccines. Rather than giving every patient the same shot, Moderna uses genetic information from each person's tumor to create a personalized mRNA vaccine designed to help their immune system recognize and attack cancer cells.

The downside is that making a separate vaccine for every patient takes time. The manufacturing process currently takes about six weeks, although Merck CEO Robert Davis said last week that the company believes it can eventually shorten that timeline.

Merck shares also fell as much as 3.9% Thursday before recovering some of those losses. Unlike Moderna, which has much riding on the success of its cancer vaccine, Merck has a much larger business supported by established treatments, including Keytruda.

At the time of publishing this article, Stocks.News holds positions in Moderna and Merck as mentioned in the article.